Secreted proteins

Abstract

Novel proteins are disclosed.

What is claimed is:  
     
         1 . A composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of: 
 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;    (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 14 to nucleotide 400;    (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM931 deposited under accession number ATCC 98026;    (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026;    (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AM931 deposited under accession number ATCC 98026;    (f) a polynudeotide encoding the mature protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026;    (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;    (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity;    (i) a polynucleotide which is an allelic variant of a polynudeotide of (a)-(f) above; and    a polynucleotide which encodes a species homologue of the protein of (g) or (h) above.    
     
     
         2 . The composition of  claim 1 , further comprising a pharmaceutically acceptable carrier.  
     
     
         3 . A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of  claim 2 .  
     
     
         4 . A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: 
 (a) the amino acid sequence of SEQ ID NO:2;    (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120;    (c) the amino acid sequence of SEQ ID NO:2 from amino acid 86 to amino acid 128;    (d) fragments of the amino acid sequence of SEQ ID NO:2; and    (e) the amino acid sequence encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026;    the protein being substantially free from other mammalian proteins.    
     
     
         5 . The composition of  claim 4 , wherein said protein comprises the amino acid sequence of SEQ ID NO:2.  
     
     
         6 . The composition of  claim 4 , wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.  
     
     
         7 . The composition of  claim 4 , wherein said protein comprises the amino add sequence of SEQ ID NO:2 from amino acid 86 to amino acid 128.  
     
     
         8 . The composition of  claim 4 , further comprising a pharmaceutically acceptable carrier.  
     
     
         9 . A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of  claim 8 .  
     
     
         10 . The composition of  claim 1  wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:1.  
     
     
         11 . The composition of  claim 1  wherein said polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 14 to nucleotide 400.  
     
     
         12 . The composition of  claim 1  wherein said polynucleotide comprises the nucleotide sequence of the full length protein coding sequence of clone AM931 deposited under accession number ATCC 98026.  
     
     
         13 . The composition of  claim 1  wherein said polynucleotide comprises a polynucleotide encoding the full length protein encoded by the cDNA insert of clone AM931 deposited under accession number ATCC 98026.  
     
     
         14 . The composition of  claim 1  wherein said polynucleotide comprises the nucleotide sequence of the mature protein coding sequence of clone AM931 deposited under accession number ATCC 98026.  
     
     
         15 . The composition of  claim 1  wherein said polynucleotide comprises a polynudeotide encoding the mature protein encoded by the cDNA insert of done AM931 deposited under accession number ATCC 98026.  
     
     
         16 . The composition of  claim 1  wherein said polynucleotide comprises a polynudeotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2.  
     
     
         17 . The composition of  claim 4  wherein said protein comprises the amino add sequence encoded by the cDNA insert of done AM931 deposited under accession number ATCC 98026.  
     
     
         18 . The method of  claim 9  wherein said subject is treated to produce an effect selected from the group consisting of inhibition of angiogenesis, inhibition of growth or proliferation of vascular endothelial cells, inhibition of tumor growth and inhibition of angiogenesis-dependent tissue growth.